With a market cap of $37.5 billion, Fiserv, Inc. (FISV) is a global provider of payments and financial services technology solutions. The company operates through two segments: Merchant Solutions and Financial Solutions, offering services such as merchant acquiring, digital commerce, mobile payments, fraud protection, card processing, and digital banking solutions. Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Fiserv fits this criterion perfectly. Fiserv serves ...

Jacksonville, Florida-based Regency Centers Corporation (REG) is a prominent REIT. It owns, manages, and develops grocery-anchored shopping centers in affluent suburban areas across the U.S. With a market cap of $12.4 billion, Regency’s portfolio includes over 480 properties and community-focused spaces offering shopping, dining, and entertainment options. Companies worth $10 billion or more are generally described as "large-cap stocks." Regency fits right into that category, with its market cap exceedin ...

Norwalk, Connecticut-based EMCOR Group, Inc. (EME) operates as one of the leading providers of mechanical and electrical construction, industrial and energy infrastructure, as well as building services for a diverse range of businesses. With a market cap of $27.9 billion, the company serves commercial, industrial, utility, and institutional clients. Companies worth $10 billion or more are generally described as "large-cap stocks." EMCOR fits right into that category, with its market cap exceeding this th ...

Core Insights - Universal Health Services, Inc. (UHS) is a significant player in the healthcare sector, operating acute care hospitals, behavioral health facilities, and outpatient services, with a market capitalization of $13.9 billion [1][2] Company Performance - UHS is classified as a large-cap stock, reflecting its substantial size and influence in the medical care facilities industry, benefiting from operational expertise and steady demand [2] - The company's stock is currently trading 9.6% below its 52-week high of $246.33, but has gained 16.1% over the past three months, outperforming the S&P 500 Index's 3.7% increase during the same period [3] - Over the past 52 weeks, UHS shares have increased by 19.4%, surpassing the S&P 500's 12.8% rise, and are up 24.1% year-to-date compared to the S&P 500's 16.1% return [4] Recent Financial Results - UHS reported better-than-expected Q3 earnings, with a 13.4% year-over-year revenue increase to $4.5 billion, exceeding consensus estimates by 4.4% [5] - The adjusted EPS rose by 53.4% from the previous year to $5.69, significantly above analyst expectations of $4.66 [5] - The company has raised its fiscal 2025 revenue and earnings guidance, indicating strong operational momentum [5] Competitive Landscape - UHS has underperformed compared to its rival HCA Healthcare, which has seen a 55.4% increase over the past 52 weeks and a 61.5% rise year-to-date [6]

Company Overview - Incyte Corporation, based in Wilmington, Delaware, has a market cap of $18.7 billion and focuses on the discovery, development, and commercialization of innovative therapeutics across the U.S., Europe, Canada, and Japan [1] - The company is classified as a "large-cap" stock, with a strong clinical-stage pipeline supported by internal research and strategic collaborations [2] Stock Performance - Incyte's shares are down 12.7% from their 52-week high of $109.28, but have risen 14.8% over the past three months, outperforming the Nasdaq Composite's 4.8% gain during the same period [3] - Year-to-date, INCY stock is up 38.1%, exceeding the Nasdaq's 20.1% increase, and has gained 34.7% over the past 52 weeks compared to the Nasdaq's 16.5% return [4] Financial Results - Incyte reported Q3 2025 results on October 28, with adjusted EPS of $2.26 and total revenue of $1.37 billion, reflecting a 20% year-over-year increase [5] - The company reported strong product performance, with Jakafi revenue at $791 million, Opzelura at $188 million, and early uptake of Niktimvo generating $46 million in sales [5] - Incyte raised its full-year 2025 net product revenue guidance to between $4.23 billion and $4.32 billion, although the stock fell 1.5% on the day of the announcement [5] Analyst Sentiment - Compared to rival Exelixis, which has gained 22.8% year-to-date and 16.2% over the past 52 weeks, Incyte's performance has been stronger [6] - Analysts maintain a consensus rating of "Moderate Buy" for Incyte, with a mean price target of $101, indicating a potential premium of 5.9% to current levels [6]

Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostic products, imaging systems, and surgical products for women's health through early detection and treatment worldwide. With a market cap of $16.7 billion, Hologic operates through Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments. Companies worth $10 billion or more are generally described as “large-cap stocks.” Hologic fits right into that category, with its market cap exceeding this ...

Company Overview - Best Buy Co., Inc. (BBY) has a market cap of $15.5 billion and is a leading multinational specialty retailer of consumer electronics, appliances, and related services, operating in the U.S. and Canada [1] - The company serves customers through various brands including Best Buy, Geek Squad, Lively, and Pacific Kitchen and Home [1][2] Stock Performance - Shares of Best Buy have declined 19.2% from their 52-week high of $91.68, and over the past three months, the shares have decreased 5.5%, underperforming the State Street SPDR S&P Retail ETF (XRT) [3][4] - Year-to-date, BBY stock is down 13.6%, while XRT has gained 10.4%, and over the past 52 weeks, BBY shares have dipped 14.9%, compared to XRT's 4.2% rise [4] - Despite this underperformance, BBY stock has risen above its 200-day moving average since late September [4] Recent Financial Results - On November 25, shares of Best Buy jumped 5.3% following better-than-expected Q3 2026 results, reporting adjusted EPS of $1.40 and revenue of $9.67 billion [5] - The company experienced enterprise comparable-sales growth of 2.7%, driven by strength in computing, gaming, and mobile phones [5] - Best Buy raised its 2026 adjusted EPS guidance to a range of $6.25 - $6.35, further boosting investor confidence [5] Analyst Sentiment - Despite underperformance compared to rivals like Ulta Beauty, which has returned 38.1% YTD, analysts maintain a moderately optimistic outlook for Best Buy [6] - The stock has a consensus rating of "Moderate Buy" from 24 analysts, with a mean price target of $83.68, representing an 11.8% premium to current levels [6]

Company Overview - Omnicom Group Inc. (OMC) is valued at a market cap of $14.9 billion and is based in New York, providing services in advertising, marketing, and corporate communications [1] - The company is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the advertising agencies industry [2] Performance Metrics - OMC's shares have slipped 17.1% below its 52-week high of $93.42, reached on December 11, 2024, and have gained 1.9% over the past three months, underperforming the Dow Jones Industrial Average's 5.6% rise [3] - Year-to-date, OMC shares are down 10%, while the Dow Jones Industrial Average has returned 13%. Over the past 52 weeks, OMC has fallen 16.3%, significantly lagging behind the Dow's 8.6% increase [4] Recent Earnings Report - On October 21, OMC reported Q3 earnings that exceeded expectations, with overall revenue climbing 4% year-over-year to $4 billion, surpassing consensus estimates [5] - The adjusted EPS advanced 10.3% from the previous year to $2.24, exceeding analyst expectations of $2.15 [5] - OMC has outperformed its rival WPP plc, which has seen a decline of 61.3% over the past 52 weeks and 57.6% year-to-date [5] Market Position - OMC works with many of the world's largest brands, offering integrated, data-driven marketing solutions through well-known agency networks like BBDO, DDB, TBWA, OMD, and FleishmanHillard [2] - The company is recognized for its creative excellence and global scale, effectively combining strategy, media, and analytics to enhance brand presence and customer engagement [2] Technical Indicators - OMC has recently started trading above its 200-day and 50-day moving averages since early December, indicating a potential bullish trend [4]

With a market cap of $15.8 billion, The Cooper Companies, Inc. (COO) is a global medical device company specializing in contact lenses and women’s health care solutions. Through its CooperVision and CooperSurgical segments, it offers advanced vision-correction lenses as well as fertility, genomics, and contraceptive products. Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Cooper Companies fits this criterion perfectly. The company serves healthcare professionals ...

Tyson Foods, Inc. (TSN), based in Springdale, Arkansas, operates a global protein empire through its Beef, Pork, Chicken, and Prepared Foods segments. It processes cattle, hogs, and chickens into fresh, frozen, and value-added products, managing iconic brands like Tyson, Jimmy Dean, Hillshire Farm, and Ball Park. The company holds a market capitalization of around $20.4 billion, which firmly places it in the “large-cap” category, as companies valued above $10 billion earn that distinction. This scale und ...